Enliven Therapeutics (ELVN) Insider Trading & Ownership $29.28 -0.27 (-0.91%) (As of 02:07 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Enliven Therapeutics (NASDAQ:ELVN) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage29.20%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)9Amount OfInsider Selling(Last 12 Months)$44.64 M Get ELVN Insider Trade Alerts Want to know when executives and insiders are buying or selling Enliven Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ELVN Insider Buying and Selling by Quarter Ad Oasis Gold"Bonds to Crash as Payback for Trump’s Win?Trump may have won, but you're not safe. JD Vance just dropped a bombshell—he's warning of a "death spiral" in the U.S. bond market that could cripple the entire economy. Here's what's happening: the U.S. is $35 TRILLION in debt.Click here to get your FREE guide now before inflation destroys your future. Enliven Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/28/2024Benjamin HohlCFOSell6,250$28.56$178,500.00 10/18/2024Anish PatelCOOSell716$30.00$21,480.00 10/18/2024Benjamin HohlCFOSell814$30.00$24,420.00 10/18/2024Joseph P LyssikatosInsiderSell847$30.00$25,410.00 10/18/2024Richard A HeymanDirectorSell817$30.00$24,510.00 10/18/2024Samuel KintzCEOSell924$30.00$27,720.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 10/15/2024Richard A HeymanDirectorSell1,270$27.67$35,140.90 10/9/2024Joseph P LyssikatosInsiderSell37,878$28.16$1,066,644.48 10/9/2024Samuel KintzCEOSell16,710$28.15$470,386.50 10/8/2024Rahul D BallalDirectorSell10,420$28.17$293,531.40 10/7/2024Benjamin HohlCFOSell1,270$27.51$34,937.70 10/7/2024Joseph P LyssikatosInsiderSell2,707$27.61$74,740.27 10/7/2024Samuel KintzCEOSell2,730$27.50$75,075.00 10/4/2024Benjamin HohlCFOSell10,218$27.51$281,097.18 10/4/2024Joseph P LyssikatosInsiderSell7,522$27.51$206,930.22 10/4/2024Richard A HeymanDirectorSell2,825$27.51$77,715.75 10/4/2024Samuel KintzCEOSell12,206$27.51$335,787.06 10/1/2024Joseph P LyssikatosInsiderSell527$27.54$14,513.58 10/1/2024Richard A HeymanDirectorSell518$27.54$14,265.72 10/1/2024Samuel KintzCEOSell526$27.54$14,486.04 9/30/2024Benjamin HohlCFOSell2,000$25.33$50,660.00 9/27/2024Benjamin HohlCFOSell4,250$24.27$103,147.50 8/29/2024Joseph P LyssikatosInsiderSell12,000$22.49$269,880.00 8/27/2024Benjamin HohlCFOSell4,250$22.54$95,795.00 8/26/2024Samuel KintzCEOSell12,000$22.89$274,680.00 8/15/2024Richard A HeymanDirectorSell1,270$23.25$29,527.50 7/31/2024Benjamin HohlCFOSell991$27.53$27,282.23 7/31/2024Joseph P LyssikatosInsiderSell3,099$27.56$85,408.44 7/31/2024Richard A HeymanDirectorSell1,702$27.51$46,822.02 7/31/2024Samuel KintzCEOSell2,270$27.56$62,561.20 7/29/2024Benjamin HohlCFOSell5,250$26.68$140,070.00 7/29/2024Joseph P LyssikatosInsiderSell12,000$26.70$320,400.00 7/25/2024Samuel KintzCEOSell12,000$24.92$299,040.00 7/15/2024Anish PatelCOOSell30,978$25.05$775,998.90 7/15/2024Richard A HeymanDirectorSell1,270$24.80$31,496.00 7/12/2024Anish PatelCOOSell17,475$25.07$438,098.25 7/12/2024Benjamin HohlCFOSell3,000$25.07$75,210.00 6/27/2024Benjamin HohlCFOSell4,250$22.57$95,922.50 6/25/2024Samuel KintzCEOSell12,000$21.66$259,920.00 6/6/2024Anish PatelCOOSell1,133$20.06$22,727.98 We recommended Nvidia in 2016, now we’re recommending this… (Ad)Greta Thunberg once called it “extremely dangerous, expensive, and time-consuming”. But now, even the High Priestess of Climate Change herself has realized the world cannot continue without this controversial “AI Keystone” technology. In fact, she’s rushing to embrace it. And she’s not the only one. Jeff Bezos just invested $130 million into it. Sam Altman, the face of AI, has put the largest investment he’s ever made into it — a cool $375 million.Watch this new investigative report here.5/28/2024Benjamin HohlCFOSell4,250$23.18$98,515.00 5/28/2024Samuel KintzCEOSell12,000$23.18$278,160.00 5/16/2024Rishi GuptaDirectorSell1,033,300$22.14$22,877,262.00 5/14/2024Anish PatelCOOSell1,107$25.00$27,675.00 5/9/2024Anish PatelCOOSell260$25.06$6,515.60 5/6/2024Anish PatelCOOSell4,875$22.72$110,760.00 5/3/2024Benjamin HohlCFOSell1,000$22.50$22,500.00 4/29/2024Benjamin HohlCFOSell3,250$16.97$55,152.50 4/29/2024Joseph P. LyssikatosinsiderSell12,000$17.92$215,040.00 4/25/2024Samuel KintzCEOSell12,000$16.89$202,680.00 4/15/2024Richard A HeymanDirectorSell1,270$19.99$25,387.30 4/11/2024Anish PatelCOOSell17,500$25.03$438,025.00 4/11/2024Benjamin HohlCFOSell14,000$24.72$346,080.00 4/11/2024Joseph P. LyssikatosinsiderSell30,000$25.04$751,200.00 4/11/2024Rahul D BallalDirectorSell53,400$23.95$1,278,930.00 4/11/2024Samuel KintzCEOSell47,709$25.04$1,194,633.36 4/8/2024Anish PatelCOOSell4,875$18.60$90,675.00 4/4/2024Rahul D BallalDirectorSell3,485$19.15$66,737.75 4/1/2024Joseph P. LyssikatosinsiderSell12,000$18.60$223,200.00 4/1/2024Rahul D BallalDirectorSell3,237$19.08$61,761.96 3/27/2024Benjamin HohlCFOSell3,250$18.25$59,312.50 3/25/2024Samuel KintzCEOSell12,000$17.56$210,720.00 3/19/2024Richard A HeymanDirectorSell1,270$14.50$18,415.00 3/6/2024Anish PatelCOOSell4,875$15.64$76,245.00 2/29/2024Joseph P. LyssikatosinsiderSell12,000$16.42$197,040.00 2/27/2024Benjamin HohlCFOSell3,250$16.97$55,152.50 2/15/2024Richard A HeymanDirectorSell1,270$17.42$22,123.40 2/6/2024Anish PatelCOOSell4,875$15.11$73,661.25 1/31/20245Am Partners Vi, LlcMajor ShareholderSell500,000$15.00$7,500,000.00 1/30/2024Richard A HeymanDirectorSell1,270$16.41$20,840.70 1/29/2024Benjamin HohlCFOSell3,250$15.81$51,382.50 1/29/2024Joseph P. LyssikatosinsiderSell12,000$15.85$190,200.00 1/25/2024Samuel KintzCEOSell12,000$15.69$188,280.00 1/22/2024Anish PatelCOOSell4,875$15.13$73,758.75 1/2/2024Anish PatelCOOSell11,000$15.00$165,000.00 1/2/2024Benjamin HohlCFOSell9,383$15.01$140,838.83 12/26/2023Anish PatelCOOSell102$15.01$1,531.02 12/26/2023Benjamin HohlCFOSell100$15.00$1,500.00 12/26/2023Samuel KintzCEOSell12,000$14.64$175,680.00 12/22/2023Anish PatelCOOSell983$15.03$14,774.49 12/22/2023Benjamin HohlCFOSell1,030$15.07$15,522.10 12/22/2023Samuel KintzCEOSell8,175$13.05$106,683.75 12/21/2023Joseph P. LyssikatosinsiderSell20$13.00$260.00 12/21/2023Richard A HeymanDirectorSell7$13.00$91.00 12/20/2023Samuel KintzCEOSell7,779$13.01$101,204.79 12/19/2023Joseph P. LyssikatosinsiderSell200$13.00$2,600.00 12/19/2023Richard A HeymanDirectorSell255$13.00$3,315.00 (Data available from 1/1/2013 forward) ELVN Insider Trading Activity - Frequently Asked Questions Who is on Enliven Therapeutics's Insider Roster? The list of insiders at Enliven Therapeutics includes 5Am Partners Vi, Llc, Anish Patel, Benjamin Hohl, Joseph P Lyssikatos, Rahul D Ballal, Richard A Heyman, Rishi Gupta, and Samuel Kintz. Learn more on insiders at ELVN. What percentage of Enliven Therapeutics stock is owned by insiders? 29.20% of Enliven Therapeutics stock is owned by insiders. Learn more on ELVN's insider holdings. Which Enliven Therapeutics insiders have been selling company stock? The following insiders have sold ELVN shares in the last 24 months: 5Am Partners Vi, Llc ($17,502,500.00), Anish Patel ($2,336,926.24), Benjamin Hohl ($1,952,998.04), Joseph P Lyssikatos ($2,063,926.99), Rahul D Ballal ($1,700,961.11), Richard A Heyman ($349,650.29), Rishi Gupta ($22,877,262.00), and Samuel Kintz ($4,548,397.78). How much insider selling is happening at Enliven Therapeutics? Insiders have sold a total of 2,837,692 Enliven Therapeutics shares in the last 24 months for a total of $55,187,384.13 sold. Enliven Therapeutics Key ExecutivesMr. Samuel S. Kintz M.B.A. (Age 38)Co-Founder, CEO, Secretary & Director Compensation: $866.41kDr. Joseph P. Lyssikatos Ph.D. (Age 59)Co-Founder & Chief Scientific Officer Compensation: $632.67kDr. Helen Louise Collins M.D. (Age 61)Chief Medical Officer Compensation: $686.19kMr. Anish Patel Pharm.D. (Age 43)Co-Founder & COO Mr. Benjamin Hohl (Age 34)CFO & Head of Corporate Development Compensation: $488.5k12 recent tradesDr. Galya D. Blachman Esq. (Age 47)Ph.D., Chief Legal Officer & Head of Business Development More Insider Trading Tools from MarketBeat Related Companies Avadel Pharmaceuticals Insider Buying Intellia Therapeutics Insider Buying Delcath Systems Insider Buying Editas Medicine Insider Buying Fulcrum Therapeutics Insider Buying bluebird bio Insider Buying CRISPR Therapeutics Insider Buying Corcept Therapeutics Insider Buying BridgeBio Pharma Insider Buying Biohaven Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics PartnersInsider Selling is not a Signal to Start Selling Gartner Stock2 Stocks to Buy and 1 to Sell - Smart Moves for Investors This page (NASDAQ:ELVN) was last updated on 11/7/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredHow high could Bitcoin go?Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
